The effect of calcitriol on renal anaemia in patients undergoing long- term dialysis

International Urology and Nephrology

Volumn 29, Issue 1, 1997, Pages 119-127

  Nazem, A K ^a   Mako J ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PHOSPHATE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; SECONDARY HYPERPARATHYROIDISM;

EID: 0030938567     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02551427     Document Type: Article

References (37)

1. Eschbach, J. W.: Erythropoietin for anemia of chronic renal failure. Am. J. Kidney Dis., 4 (Suppl. 1), 3 (1991).
2. Eschbach, J. W., Egrie, J. E., Browne, J. K., Adamson, J. W., Downing, M. R.: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N. Engl. J. Med., 316, 73 (1987).
3. Bauer, C., Koch, K. M., Scigalla, P., Wieczorek, L.: Erythropoietin Molecular Physiology and Clinical Applications. Marcel Dekker, Inc., New York 1993, p. 81.
4. Bauer, C., Koch, K. M., Scigalla, P., Wieczorek, L.: Erythropoietin Molecular Physiology and Clinical Applications. Marcel Dekker, Inc., New York 1993, p. 107.
5. Drücke, T.: Modulating factors in the hematopoietic response to erythropoietin. Am. J. Kidney Dis., 4 (Suppl. 1), 87 (1991).
6. Stivelman, J. C.: Resistance to recombinant human erythropoietin therapy: A real entity? Semin. Nephrol., 9, 8 (1989).
7. Koury, M. J.: Investigating erythropoietin resistance. N. Engl. J. Med., 328, 205 (1993).
8. Makó, J., Mérei, J., Szũcs, J., Gellei, A.: Reduction in the requirement for transfusions in long-term haemodialysis patients following subtotal parathyroidectomy (in Hungarian). Orv. Hetil., 122, 4 (1981).
9. Szũcs, J., Makó, J., Mérei, J.: Blood requirement and subtotal parathyroidectomy in patients with chronic renal failure treated with hemodialysis. Clin. Nephrol., 3, 134 (1983).
10. Makó, J., Potyondi, M., Szelke, L., Nazem, A. K.: Two years' experience with Recormon therapy (in Hungarian). Magy. Belorv. Arch., 47 (Suppl. 1), 182 (1994).
11. Slatopolsky, E., Delmez, J. A.: Pathogenesis of secondary hyperparathyroidism. Int. Proc. J., 5, 3 (1993).
12. Urena, P., Eckard, K. W., Sarfati, E., Zingraff, J., Roullet, J. B., Roland, E., Drüeke, T., Kurtz, A.: Serum erythropoietin and erythropoiesis in primary and secondary hyperparathyroidism. Effect of parathyroidectomy. Nephron, 59, 384 (1991).
13. Zingraff, J., Drüeke, T., Marie, P., Man, N. K., Jungers, P., Bordier, P.: Anemia and secondary hyperparathyroidism. Arch. Int. Med., 138, 1650 (1978).
14. Zachée, P., Vanuytsel, J., Daelemans, R., Lins, R. L.: Anaemia and renal osteodystrophy. 31st Ann. Congr. EDTA-ERA, Vienna, Austria 1994, Abstract.
15. Rao, D. S., Shih, M. S., Mohini, R.: Effect of serum parathyroid hormone and bone marrow on the response to erythropoietin in uremia. N. Engl. J. Med., 328, 171 (1993).
16. Bertiu, A., Fernandez, E., Cao, G., Rivas, M. C., Montoliu, J.: Effect of sequential increment in the dose of i.v. calcitriol on severe hyperparathyroidism. 31st Ann. Congr. EDTA-ERA, Vienna, Austria 1994, Abstract.
17. Bocchini, G., Fabrizi, F., Locotelli, F.: Pulse oral calcitriol vs. intravenous in severe secondary hyperparathyroidism. 31st Ann. Congr. EDTA-ERA, Vienna, Austria 1994, Abstract.
18. Slatopolsky, E., Weerts, C., Thielan, J., Horst, R., Harter, H., Martin, J. K.: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25 dihydroxycholecalciferol in uremic patients. J. Clin. Invest., 74, 2136 (1984).
19. Llach, F.: Treatment of secondary hyperparathyroidism. Int. Proc. J., 5, 13 (1993).
20. 3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis. Nephron, 53, 194 (1989).
21. Malberti, F., Surian, M., Cosci, P.: Improvement of secondary hyperparathyroidism and reduction of the set point of calcium after intravenous calcitriol. Kidney Int., 43 (Suppl. 41), S-125 (1993).
22. Norris, K. C., Kraut, J. A., Andress, D. L.: Intravenous calcitriol: Effect in severe hyperparathyroidism. J. Bone Miner. Res., 1 (Suppl. 1), 374 (1986).
23. Masafumi, F., Masafumi, K., Hung, Y., Naoko, F., Toshio, M., Esturó, O., Kiyoshi, K.: Serial evaluation of parathyroid gland size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron, 68, 221 (1994).
24. Cubero, J., Caravaco, F., Jimenez, F., Lopez, J. M., Aparicio, A., Cid, M. C., Pizzaro, J. L., Liso, J., Santos, J.: Effect of the mode of calcitriol administration on iCa-PTH relationship: A randomized clinical trial. 31st Ann. Congr. EDTA-ERA, Vienna, Austria 1994, Abstract.
25. Andress, D. L., Norris, K. C., Coburn, J. W., Slatopolsky, E., Sherrard, D. J.: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N. Engl. J. Med., 321, 274 (1989).
26. Argilés, A., Mourad, G., Lorcho, R., Kerr, P. G., Flavier, J. L., Canaud, B., Mion, C. M.: Medical treatment of severe hyperparathyroidism and its influence on anaemia in end-stage renal failure. Nephrol. Dial. Transplant., 9, 1809 (1994).
27. Kerley, J. A., Hattersley, G., Collins, D. A., Chambers, T. J.: Derivation of osteoclast from hematopoietic colony-forming cells in culture. J. Bone Miner. Res., 7/3, 353 (1993).
28. Thomasset, M.: Vitamin D and immune system. Pathol. Biol., 42/2, 163 (1994).
29. Riancho, A. J., Zarrabeitia, T. M., De Francisco, L. M. A., Amado, A. J., Napal, J., Arias, M., Gonzales-Macias, J.: Vitamin D therapy modulates cytokine secretion in patients with renal failure. Nephron, 65, 364 (1993).
30. Votta, B. J., Betolini, D. R.: Cytokine suppressive anti-inflammatory compounds inhibit bone resorption in vitro. Bone, 5, 533 (1994).
31. Clibon, U., Bonewald, L., Caro, J.: Erythropoietin fails to reverse the anaemia in mice continuously exposed to tumor necrosis factor-alfa in vivo. Exp. Hematol., 18, 438 (1990).
32. Wilson, J. G., Tavassoli, M.: Microenvironmental factors involved in the establishment of erythropoiesis in bone marrow. Ann. N. Y. Acad. Sci., 718, 271 (1994).
33. Kubane, B.: The role of the microenvironment and cytokines on the modulation of erythropoiesis. Ann. N. Y. Acad. Sci., 718, 257 (1994).
34. Chuncharunee, S., Carter, C. D., Studtmann, K. E., Caro, J., Coffey, R. J., Dessypris, E. N.: Chronic administration of transforming growth factor-beta suppresses erythropoietin-dependent erythropoiesis and induces tumor necrosis factor in vivo. Br. J. Haematol., 84, 374 (1993).
35. Ryan, J. R. J., Beynon, L. C. H., Rees, W. J. A., Kassidy, M.: In vitro production of tumor necrosis factor by monocytes cultured from dialysis patients. Kidney Int., 43 (Suppl. 41), S-226 (1993).
36. Petrosa, G., Tarantino, E. A., Gesualdo, L., Montinaro, V., Schena, P. F.: C5b-9 generation and cytokine production in hemodialyzed patients. Kidney Int., 43 (Suppl. 41), S-221 (1993).
37. Descamps-Latscha, B., Herbelin, A.: Long term dialysis and cellular immunity: A critical survey. Kidney Int., 43 (Suppl. 41), S-135 (1993).